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Abstract: We studied the time interval between starting tuberculosis
treatmentandcommencingantiretroviraltreatment(ART)inHIV-infected
patients(n=1433;medianCD4count71cellspermicroliter,interquartile
range: 32–132) attending 3 South African township ART services
between 2002 and 2008. The overall median delay was 2.66 months
(interquartile range: 1.58–4.17). In adjusted analyses, delays varied
between treatment sites but were shorter for patients with lower CD4
counts and those treated in more recent calendar years. During the most
recent period (2007–2008), 4.7%, 19.7%, and 51.1% of patients started
ART within 2, 4, and 8 weeks of tuberculosis treatment, respectively.
OperationalbarriersmustbetackledtopermitfurtheraccelerationofART
initiation as recommended by 2010 WHOART guidelines.
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INTRODUCTION
The high mortality risk of patients with HIV-associated
tuberculosis (TB) is reduced by 64%–95% by antiretroviral
therapy (ART).
1 However, the optimal time to start ART
during TB treatment has for a long time remained unclear.
Findings from observational studies and recent randomized
controlled trials have demonstrated that delayed ARTinitiation
is associated with increased mortality risk across a wide
spectrum of baseline CD4 cell counts.
2–6 The World Health
Organization (WHO) has updated ART guidelines on several
occasions between 2002 and 2010, recommending progres-
sively higher CD4 cell count thresholds for ARTeligibility and
more rapid initiation of ART during TB treatment.
7 Guidelines
published in 2010 recommend ART be given to all patients
with HIV-associated TB regardless of CD4 cell count and
that this be started as soon as possible after TB treatment is
tolerated and not later than 8 weeks.
7
The operational feasibility of early initiation of ART in
TB patients under routine program conditions in resource-
limited settings is not known, however. The timing of ART
may be inﬂuenced by many factors, including delays asso-
ciated with HIV testing and CD4 cell count measurement,
constraints within the health system that contribute to delays
in referral and access to ART clinics, and changes in pro-
grammatic efﬁciency and clinical expertise over time. In this
study, we quantiﬁed and explored factors associated with
delays between starting TB treatment and starting ARTamong
TB patients enrolling in 3 large community-based ART
services in townships in South Africa.
METHODS
Antiretroviral Treatment Cohorts
Provision of ART within 3 primary care clinics in the
townships of Khayelitsha, Gugulethu, and Masiphumelele in
Cape Town, South Africa, started between 2001 and 2003.
8–13
ART was provided free of charge under the South African
national guidelines for patients with WHO stage 4 disease
and all those with blood CD4 cell counts ,200 cells per
microliter.
14 The huge burden and complications of TB in
these services has been previously reported.
9,15–17 TB treat-
ment and ART in South Africa are typically delivered by
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16 TB was treated using
standardized rifampicin-based regimens of 6 months duration
for new TB cases and 8 months for retreatment cases. The total
treatment period, however, was longer for those with treatment
interruptions or drug-resistant disease.
Data Sources
Each of the clinics participates in the International
epidemiological Databases to Evaluate AIDS in Southern
Africa network (www.iedea-sa.org). Prospective clinical
databases have been maintained for all patients enrolling in
these services.
9,11,12 All sites obtained ethical approval from
relevant local institutions before contributing anonymized
patient data collected between 2002 and 2008 to this
collaborative analysis. Data were included from patients aged
older than 18 years who had a notiﬁed diagnosis of TB,
initiated ART for the ﬁrst time during the course of TB
treatment, and were followed up for a minimum period of
10 months from TB diagnosis during which ART could be
started. For each patient, demographic details, TB classiﬁca-
tion, WHO clinical stage, blood CD4 cell counts, and dates
of TB diagnosis and ART initiation were recorded. Where
details of TB diagnoses were missing, these were sought from
clinic TB registers and the Cape Town electronic TB register.
Statistical Analyses
Patient characteristics were summarized by calendar
period of starting TB treatment. Data were aggregated into
4 sequential calendar periods, 2002–2004, 2005, 2006, and
2007–2008, such that there were at least 200 patients
represented in each period. The time from start of TB
treatment to start of ARTwas the outcome of primary interest.
Accelerated failure time (AFT) models were used to
determine crude and adjusted associations between hypoth-
esized risk factors and time to initiation of ART. The AFT
metric was chosen because of its speciﬁc reference to time
and impact on time and because the proportional hazards
assumption was not satisﬁed by the data. The Weibull,
generalized gamma, log-logistic, lognormal, and exponential
AFT models were each considered. The gamma model had
the lowest values for the Akaike Information Criteria and
Bayesian Information Criteria. The Wald test on the 2-shape
parameters conﬁrmed that none of the simpler distributions
were appropriate. The gamma model had the best model ﬁt
based on a graph plotting the Cox-Snell residuals against the
cumulative hazard of time. The coefﬁcients of the generalized
gamma AFT model were transformed to acceleration coefﬁ-
cients by taking the exponent of the negative coefﬁcient. These
acceleration coefﬁcients measure the relative acceleration
(and associated shortening of time) to ART initiation.
RESULTS
Patient Characteristics
During the analysis period, 1433 patients who started
ART during TB treatment were eligible for inclusion. Patients
were adults with a median age of 33 years [interquartile range
(IQR): 29–39] and 60% were women. Sixty one per cent
were recorded as having pulmonary disease alone, and 39%
had extrapulmonary disease with or without concomitant
pulmonary involvement. Treatment for recurrent TB was
received by 29% of patients. CD4 counts were available for
1152 (80.4%) patients with a median of 71 cells per microliter
(IQR: 32–132). When stratiﬁed by calendar period, patient
characteristics did not vary substantially (see Table, Supple-
mental Digital Content 1, http://links.lww.com/QAI/A157)
although the proportion of patients who were male tended to
increase over time and the proportion of patients receiving
a retreatment TB regimen decreased over time.
Time to Initiation of ART
The time between starting TB treatment and starting
ARTwas highly variable with a median of 2.66 months (IQR:
1.58–4.17). Using AFT models (Table 1), crude analyses
showed that delayswere shorter among younger patients, those
with a ﬁrst episode of TB, sputum smear-positive disease,
lower CD4 cell counts, and treatment in later calendar periods.
However, in fully adjusted models, only 3 variables remained
signiﬁcantly associated with time to ARTas follows: the blood
CD4 cell count, calendar year, and the treatment site (Table 1).
The longest predicted delays between start of TB
treatment and ART initiation were among those with blood
CD4 cell counts of $200 cells per microliter who started TB
treatment during the calendar period 2002–2004 at site 2; the
average time was 4.73 months (95% conﬁdence interval: 4.12
to 5.33). Time to ART initiation was signiﬁcantly accelerated
among thosewith lower CD4 counts (Fig. 1A). In patients with
CD4 counts of 100–199, 50–99, and ,50 cells per microliter,
time to starting ARTwas accelerated by 20%, 34%, and 75%,
respectively (Table 1), giving mean times of 3.95, 3.53, and
2.77 months. Similarly, mean times were accelerated among
patients treated in calendar periods 2005, 2006, and 2007–
2008 by 8%, 22%, and 39%, respectively, giving mean times
of 4.36, 3.87, and 3.41 months (Fig. 1B). Considerable
heterogeneity in time to ART start was also observed between
the 3 different treatment sites (Fig. 1C), although the
associations with CD4 cell count and calendar period were
observed at all 3 sites. The shortest predicted delays between
start of TB treatment and ART initiation were among those
with a blood CD4 cell count of ,50 cells per microliter who
started TB treatment during the calendar period 2007–2008 at
site 3; the average time was 1.28 months (95% conﬁdence
interval: 1.15 to 1.42).
Comparison With 2010 WHO Guidelines
WHO ART guidelines (2010 revision) recommend that
ART should be started as soon as possible within 2–8 weeks
of starting TB treatment, regardless of CD4 cell count. We
examined the timing of ART among patients treated in the
most recent calendar period, 2007–2008. The proportions
starting ARTwithin 2, 4, 6, and 8 weeks of TB treatment were
4.7% (n = 11), 19.7% (n = 46), 35.6% (n = 83), and 51.1%
(n = 119), respectively. For those with the most advanced
immunodeﬁciency (CD4 count less than 50 cells/mL) treated
in this period, the corresponding percentages were 6.2%
(n = 5), 33.3% (n = 27), 61.7% (n = 50), and 77.8% (n = 63).
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The use of ART must be carefully optimized to
maximize the beneﬁt for patients with HIV-associated TB.
This study found that the time interval between starting TB
treatment and starting ART among patients treated under
routine program conditions was prolonged but highly variable
and strongly associated with 3 key factors. Delays varied
between different clinics but were shorter for those with lower
CD4 counts and for those treated in more recent calendar
periods. However, delays must be reduced much further as
recommended by current WHO guidelines.
The numbers of patients referred to ART clinics with
a TB diagnosis has increased over time such that these
comprised over one-third of all referrals to ART services in
Cape Town by 2008.
9,16 In addition, intensive TB screening
just before ART initiation has found that up to 25% of other
referrals also have sputum culture-positive TB.
18,19 These
patients typically have low CD4 counts and high mortality
risk. Data from a randomized controlled trial conducted in
Cambodia (the CAMELIA trial)
5 found that TB patients with
advanced immunodeﬁciency (median CD4 cell count, 25 cells
per microliter) had 34% higher greater mortality if they
received ART after 2 months of TB treatment rather than
starting ART within the ﬁrst 2 weeks, showing the need for
rapid initiation in this group.
5
Overall, we found a strong graded relationship between
CD4 count and timing of ARTwith progressively more rapid
ART initiation among those in lower CD4 count strata. These
data may reﬂect growing clinical expertise and recognition of
the need for greater rapidity of ART among those with
advanced immunodeﬁciency.
10,15 However, despite local and
international guidelines, only one-third of patients with CD4
counts of ,50 cells per microliter treated in 2007–2008
received ARTwithin the ﬁrst 1 month of TB treatment, which
may suggest the existence of constraints within the care
pathway (such as referral delays between TB and ART
clinics)
16 to achieving more rapid ART initiation.
Delays in initiation of ART diminished substantially
betweensequentialcalendarperiodsandthismayreﬂectgrowing
awareness over time of the high mortality risk associated with
TABLE 1. Crude and Adjusted Analyses Showing Factors Associated With Time to Starting Antiretroviral Therapy (ART) Among
Patients With HIV-associated Tuberculosis (TB).
Crude Accelerators 95% CI P* Adjusted Accelerators 95% CI P*
Age category at start of TB treatment 0.008
$40 (baseline) 1 — — — — —
25–39 1.12 1.04 to 1.21 0.003 — — —
18–24 1.15 1.02 to 1.30 0.022 — — —
Gender
Male 1 — — — — —
Female (baseline) 1.01 0.94 to 1.07 0.879 — — —
Clinic ,0.001 ,0.001
2 (baseline) 1 — — 1 — —
1 1.08 1.00 to 1.15 0.046 1.39 1.29 to 1.48 ,0.001
3 1.34 1.21 to 1.48 ,0.001 1.56 1.42 to 1.71 ,0.001
Year started TB treatment ,0.001 ,0.001
2002–2004 (baseline) 1 — — 1 — —
2005 1.08 0.98 to 1.18 0.111 1.08 0.99 to 1.19 0.079
2006 1.34 1.23 to 1.46 ,0.001 1.22 1.12 to 1.33 ,0.001
2007–008 1.83 1.65 to 2.03 ,0.001 1.39 1.25 to 1.54 ,0.001
CD4 count categories (cells/mL)† ,0.001 ,0.001
$200 (baseline) 1 — — 1 — —
100–199 1.16 1.03 to 1.32 0.017 1.20 1.07 to 1.34 0.002
50–99 1.29 1.14 to 1.47 ,0.001 1.34 1.19 to 1.50 ,0.001
0–49 1.70 1.49 to 1.94 ,0.001 1.75 1.55 to 1.98 ,0.001
Classiﬁcation of TB
Retreatment (baseline) 1 — — — — —
New TB case 1.11 1.03 to 1.19 0.004 — — —
Type of TB 0.018
Smear-negative pulmonary TB (baseline) 1 — — — — —
Extrapulmonary TB 1.05 0.97 to 1.13 0.262 — — —
Smear-positive pulmonary TB 1.12 1.04 to 1.22 0.005 — — —
Shape parameters of multivariate gamma model: kappa = 0.7 (95% CI: 0.57 to 0.84); sigma = 0.42 (95% CI: 0.39 to 0.45) for all strata other than CD4 count less than 50 cells per
microliter (sigma = 0.59, 95% CI:0.50 to 0.69) and clinic 1 (sigma = 0.51, 95% CI: 0.44 to 0.60).
*The P value in line with the heading of each variable with more than 2 categories was calculated using the Wald Test.
†CD4 count taken closest start of TB treatment that satisﬁed criteria of being taken not earlier than 183 days before or 91 days after start of TB treatment and not more than 7 days
after start of ART.
CI, conﬁdence interval.
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10 and more efﬁcient HIV testing procedures.
After 2005, a traditional model of voluntary counselling and
testing for HIV with very poor uptakewas replaced by a model
of provider-initiated testing and counselling, which has
achieved testing rates of more than 90% in local TB clinics.
16
Provider-initiated testing and counselling is likely to have
resulted in increases in the numbers of TB patients referred for
ART and the rapidity with which this is done.
There were differences in the timing of ART among
patients attending the three separate treatment sites that were
independent of other variables. This may reﬂect differences in
referral processes and patient accessibility to ART services or
differences in the clinical decision making process. Further
operational research studies are needed to better characterize
the various component delays associated with different models
of care. In particular, as individual sites move toward
integration of TB treatment and provision of ART, the impact
on timing of ART should be investigated and timing might be
used as an indicator the quality of care.
The 2010 WHO ART guidelines and South African
national ART guidelines recommend ART be started as soon
as TB treatment is tolerated and not later than after 8 weeks.
20
However, in the most recent calendar period (2007–2008),
only 1 half of patients started ART within an 8-week time
frame. Much progress now needs to be made in identifying the
operational barriers to more rapid ART initiation. Integration
of TB care and ART in the same clinic would be likely to
decrease these delays. However, this may also be associated
FIGURE 1. Gamma survival curves showing the
proportion of patients who have yet to start ART
(survival) with increasing duration of TB treatment
(analysis time in months). Data are adjusted for
other covariates shown in Table 1 with the
reference group in each plot representing patients
with CD4 cell counts in the range 100–199 cells
per microliter cared for at treatment site 3 in 2005.
Data are shown stratiﬁed by the following: A,
blood CD4 cell count; B, calendar year of starting
treatment; and C, treatment site.
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ease,
5,17,21 which will require appropriate management, and
nosocomial TB transmission,
22 which require improved
infection control measures.
Strengths of this study include the large number of
patients analyzed; the patient populations attending primary
care ART cohorts were typical of public sector ART clinics in
the southern African region; careful prospective recording of
patient data, and inclusion of patients enrolled over a 7-year
period permitting analysis of temporal trends. Weaknesses of
the study include the retrospective study design and lack of
identiﬁcation of the constituent delays contributing to the
overall delay in starting ART. The clinical consequences of
delays in ART initiation have not been demonstrated and
patients who died or were lost to follow-up before initiating
ART have not been quantiﬁed. Further operational research is
needed to study the impact of interventions to accelerate ART
access and the time to starting ART should be prospectively
monitored within programs.
In conclusion, the timing of ART among TB patients
attending 3 large ART services in townships around Cape
Town was very heterogeneous. However, delays decreased
substantially over a 7-year period and those with lower CD4
cell counts received ART more rapidly. New WHO ART
guidelines and national ART guidelines now recommend
much greater acceleration of ART initiation among all TB
patients, which is likely to require models of care with much
better integration of TB and ART treatment.
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